| Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches JA Welsh, DCI Goberdhan, L O'Driscoll, EI Buzas, C Blenkiron, ... Journal of extracellular vesicles 13 (2), e12404, 2024 | 3080 | 2024 |
| The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification A Rowland, JO Miners, PI Mackenzie The international journal of biochemistry & cell biology 45 (6), 1121-1132, 2013 | 819 | 2013 |
| Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials MJ Sorich, MD Wiese, A Rowland, G Kichenadasse, RA McKinnon, ... Annals of Oncology 26 (1), 13-21, 2015 | 666 | 2015 |
| Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer A Rowland, MM Dias, MD Wiese, G Kichenadasse, RA McKinnon, ... British journal of cancer 112 (12), 1888-1894, 2015 | 412 | 2015 |
| The UDP-glycosyltransferase (UGT) superfamily: new members, new functions, and novel paradigms R Meech, DG Hu, RA McKinnon, SN Mubarokah, AZ Haines, PC Nair, ... Physiological reviews 99 (2), 1153-1222, 2019 | 403 | 2019 |
| Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non–small cell lung cancer G Kichenadasse, JO Miners, AA Mangoni, A Rowland, AM Hopkins, ... JAMA oncology 6 (4), 512-518, 2020 | 338 | 2020 |
| In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction A Rowland, DJ Elliot, JA Williams, PI Mackenzie, RG Dickinson, ... Drug Metabolism and Disposition 34 (6), 1055-1062, 2006 | 281 | 2006 |
| Renal drug metabolism in humans: the potential for drug–endobiotic interactions involving cytochrome P450 (CYP) and UDP‐glucuronosyltransferase (UGT) KM Knights, A Rowland, JO Miners British journal of clinical pharmacology 76 (4), 587-602, 2013 | 260 | 2013 |
| Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers AM Hopkins, A Rowland, G Kichenadasse, MD Wiese, H Gurney, ... British Journal of Cancer 117 (7), 913-920, 2017 | 203 | 2017 |
| The “albumin effect” and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 … A Rowland, KM Knights, PI Mackenzie, JO Miners Drug Metabolism and Disposition 36 (6), 1056-1062, 2008 | 197 | 2008 |
| Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation A Rowland, P Gaganis, DJ Elliot, PI Mackenzie, KM Knights, JO Miners The Journal of pharmacology and experimental therapeutics 321 (1), 137-147, 2007 | 181 | 2007 |
| CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated … MJ Sorich, A Rowland, RA McKinnon, MD Wiese Circulation: cardiovascular genetics 7 (6), 895-902, 2014 | 152 | 2014 |
| The “albumin effect” and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and … A Rowland, DJ Elliot, KM Knights, PI Mackenzie, JO Miners Drug metabolism and disposition 36 (5), 870-877, 2008 | 102 | 2008 |
| Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for NSCLC: pooled analysis of clinical trials MJ Sorich, A Rowland, CS Karapetis, AM Hopkins Journal of Thoracic Oncology 14 (8), 1440-1446, 2019 | 101 | 2019 |
| Concomitant antibiotic use and survival in urothelial carcinoma treated with atezolizumab AM Hopkins, G Kichenadasse, CS Karapetis, A Rowland, MJ Sorich European Urology 78 (4), 540-543, 2020 | 100 | 2020 |
| Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia JO Miners, N Chau, A Rowland, K Burns, RA McKinnon, PI Mackenzie, ... Biochemical Pharmacology 129, 85-95, 2017 | 99 | 2017 |
| Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab AM Hopkins, G Kichenadasse, CS Karapetis, A Rowland, MJ Sorich Clinical Cancer Research 26 (20), 5487-5493, 2020 | 98 | 2020 |
| Current safeguards, risk mitigation, and transparency measures of large language models against the generation of health disinformation: repeated cross sectional analysis BD Menz, NM Kuderer, S Bacchi, ND Modi, B Chin-Yee, T Hu, C Rickard, ... bmj 384, 2024 | 97 | 2024 |
| Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins KJ Barnes, A Rowland, TM Polasek, JO Miners European journal of clinical pharmacology 70 (9), 1097-1106, 2014 | 97 | 2014 |
| Plasma extracellular nanovesicle (exosome)‐derived biomarkers for drug metabolism pathways: a novel approach to characterize variability in drug exposure A Rowland, W Ruanglertboon, M Van Dyk, D Wijayakumara, LS Wood, ... British journal of clinical pharmacology 85 (1), 216-226, 2019 | 91 | 2019 |
Michael SorichProfessor of Clinical Pharmacology, Flinders UniversityVerified email at flinders.edu.au
